Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue;Anticuerpos neutralizantes contra el virus de la fiebre amarilla 17 D en Colombianos vacunados y no vacunados con inmunidad a dengue

Revista de Salud Publica

Volumn 10, Issue 5, 2008, Pages 796-807

  Gómez, Sergio Y ^a   Ocazionez, Raquel E ^a  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

Flavivirus; Neutralisation test; Yellow fever; Yellow fever vaccine

Indexed keywords

VIRUS ANTIGEN; YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COLOMBIA; DENGUE; FEMALE; HUMAN; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; STATISTICS; VACCINATION; YELLOW FEVER;

ADOLESCENT; ADULT; AGED; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; COLOMBIA; DENGUE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 68849098891     PISSN: 01240064     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Monath T. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20.
2. World Health Organization. Yellow fever situation in Africa en South America. Weekly epidemiological record 2006;81;317-324.
3. Burke D, Monath T. Flavivirus. En: Knipe D, Howley P, Griffin D, Lamb R, Martin M, Roizman B, Straus S, eds. Fields Virology. Fourth edition. Philadelphia: Lippincott Williams and Wilkins; 2001. pp 1043-1126.
4. Price W, Thind I. Protection against West Nile virus induced by a previous injection with dengue virus. Am J Epidemiol. 1971; 94:596-606.
5. Bond J, Hammon W. Epidemiological studies of possible cross-protection between dengue and St. Louis encephalitis arboviruses in Florida. Am J Epidemiol 1970;92:321-330.
6. Xiao S-Y, Guzman H, Travassos da Rosa A, Zhu H-B, Tesh R. Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses. Am J Trop Med Hyg. 2003; 68:695-703.
7. Theiler M, Anderson C. The relative resistance of dengue-immune monkeys to yellow fever virus. Am J Trop Med Hyg. 1975; 24:115-117.
8. Theiler M, Smith H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937; 65:787-800.
9. World Health Organization. Standards for the manufacture and control of yellow fever vaccine. United Nations Relief and Rehabilitation Administration. World Health Organ Epidemiol Bull.1945; I:1-365.
10. Groot H. Sesenta años de vacuna antiamarílica. Biomédica 1999;19:269-271.
11. Monath T. Yellow fever vaccine. Expert Rev Vaccines 2005;4:553-574.
12. Belmusto-Worn V, Sanchez J, McCarthy K, Nichols R, Bautista C, Magill A, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005;72:189-197.
13. Tavares-Neto J, Freitas-Carvalho J, Teixeira M, Rocha G, Guerreiro S, Damasceno E, et al. Pesquisa de anticorpos contra arbovírus e o vírus vacinal da febre amarela em uma amostra da população de Rio Branco, antes e três meses após a vacina 17D. Rev Soc Bra Med Trop. 2004; 37:1-6.
14. Guerra H, Sardinha T, da Rosa A, Lima e Costa M. Effectiveness of the yellow fever vaccine 17D: an epidemiologic evaluation in health services. Rev Panam Salud Publica 1997;2:115-120.
15. Lopes O, Guimaraes S, Carvalho R. Studies on yellow fever vaccine. III-Dose response in volunteers. J Biol Stand. 1988;16:77-82.
16. Aguirre C. Fiebre Amarilla. Revista Médica de Bogotá1904; 285:198-208.
17. Peña A, Serpa R, Bevier G. Yellow fever in Colombia with special reference to epidemic in Socorro in 1920. J Prev Med. 1930:4; 417-457.
18. Velandia M. Fiebre Amarilla y su control. Biomédica. 2004; 24:5-6.
19. Derecho a la salud: Evolución de algunos indicadores de interés en salud pública. [Internet]. Disponible en: http://www.minproteccionsocial.gov.co/vbecontent/library/documents/ DocNews No15417DocumentNo2666.PDF. Consultado 10/03/2007.
20. Groot H, Gast A. Observaciones sobre la vacuna de virus 17D contra fiebre amarilla aplicada por escarificación cutánea. Rev Invest (Guadalajara). 1965; 5:5-25.
21. Ocazionez R, Cortés F, Gómez S. Serotipo, Patrón de infección y dengue hemorrágico en área endémica colombiana. Rev Salud Publica (Bogotá). 2007; 9:262-274.
22. Ocazionez R, Cortés F, Villar L, Gómez S. Temporal distribution of dengue virus serotypes in Colombian endemic area and dengue incidence. Re-introduction of dengue-3 associated to mild febrile illness and primary infection. Mem Inst Oswaldo Cruz 2006; 101:725-731.
23. Niedrig M, Laderman M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemaglutination inhibition test, immunofluorescence assay and ELISA. Trop Inf Int Health 1999; 4:867-871.
24. Monath T, Nichols R, Archambault W, Moore L, Marchesani R, Tian J, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YFVAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66:533-541.
25. Fox J, Cabral A. The duration of immunity following vaccination with the 17D strain of yellow fever virus. Am J Hyg. 1943;37:93-120.
26. Groot H, Kerr JA, Sanmartin CV. Antibodies to yellow fever and other arthropod-borne viruses in human residents of San Vicente de Chucuri, Santander, Colombia. Am J Trop Med Hyg. 1959;8:175-189.
27. Rosenzweig E, Babione R, Wisseman J. Immnunological studies with group B arthropodborne viruses, IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg. 1963;12:230-235.
28. Smithburn K, Mahaffy A. Immunization against yellow fever: studies on time of development and duration of induced immunity. Am J Top Med 1945;25:217-223.
29. Poland J, Calisher C, Monath T, Downs W, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull WHO 1981; 59:895-900.
30. Groot H, Ribero R. Neutralizing and haemaglutination-inhibition antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull WHO 1962;27: 699-707.
31. Querec T, Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D. Adv Exp Med Biol 2007; 590:43-53.
32. Barba-Spaeth G, Longman R, Albert M, Rice C. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med. 2005; 202:1179-1184.
33. Santos A, Bertho A, Dias D, Santos J, Marcovistz R. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus. Mem Inst Oswaldo Cruz 2005;100:331-337.
34. Calisher C, Karabatsos N, Darlymple J, Shope R, Porterfield J, Westaway E, et al. Antigenic relationship between Flavivirus as determined by cross-neutralization test with polyclonal antisera. J Gen Virol. 1989;70:37-43.
35. Gómez S, Ocazionez R. Neutralización del virus de la fiebre amarilla por anticuerpos antidengue como factor que puede contribuir a la ausencia de casos urbanos. Biomédica. XIII Congreso Colombiano de Parasitología y Medicina Tropical. 2007;27(2):158
36. Monath T, Craven R, Adjukiewicz A, Germain M, Francy D, Ferrara L, et al. Yellow fever in the Gambia, 1978-1979: epidemiologic aspect with observations on the occurrence of Orungo virus infections. Am J Trop Med Hyg. 1980:29;912-928.
37. Ashcroft M. Historical evidence of resistance to yellow fever acquired by residence in India. Trans R Soc Trop Med Hyg.1979; 73: 247-248.